The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines
复制标题
DOI：
10.1016/j.vaccine.2007.08.014
复制
发表时间：
2007-10-16
期刊：
影响因子：
5.5
通讯作者：
Murphy, Brian R.
中科院分区：
文献类型：
--
作者：
Wright, Peter F.;Karron, Ruth A.;Murphy, Brian R.
在呼吸道合胞病毒（RSV）疫苗开发的早期，儿童在接种福奴西林活化的RSV疫苗后发生严重疾病。持续努力开发适当减毒和免疫原性的RSV活疫苗，为通过疫苗接种后对儿童的监测来确保活疫苗的安全性提供了机会。在本研究中，388名儿童中RSV相关上呼吸道疾病的发生率在RSV疫苗接种儿童中低于对照组（6-24个月组为14% vs 20%，婴儿组为16% vs 25%）。此外，没有证据表明接种疫苗易导致更严重的下呼吸道疾病。因此，用一系列减毒活RSV疫苗感染不会导致在用野生型RSV感染后疾病增强。RSV在此次监测期间的影响将为RSV疫苗未来有效性研究的设计提供信息。(c)2007爱思唯尔有限公司保留所有权利。
Early in the development of respiratory syncytial virus (RSV) vaccines severe disease occurred in children after receipt of fornualinin-activated RSV vaccine. Continuing efforts to develop an appropriately attenuated and immunogenic live RSV vaccine have given opportunities to assure that live vaccines are safe through surveillance of children after vaccination. In the present study, the rate of RSV-associated upper respiratory tract illness in 388 children was lower in RSV vaccinated children than in controls (14% versus 20% in a 6-24 month old group and 16% versus 25% in infants). Additionally, there was no evidence that vaccination predisposed to more severe lower respiratory tract illness. Thus infection with a series of live attenuated RSV vaccines did not result in enhanced disease upon infection with wild type RSV. The impact of RSV during this surveillance will inform the design of future efficacy studies with RSV vaccines. (c) 2007 Elsevier Ltd. All rights reserved.